Advanced Drug Research Navigator! Huimed Upgraded to AIMed: AI Empowers Translational Medicine to Accurately Tackle Overseas Patent Barriers
AI technology is accelerating the bridging of the 'Valley of Death' in pharmaceutical research and development. Hangzhou Huimed Technology upgraded its brand to "AIMed" in February 2026, aiming to become an intelligent connector and enabler of translational medicine, dedicated to closing the gap between laboratory research and clinical application. The company was founded by Jin Xia, a member of the Zhejiang Provincial Committee of the Chinese People's Political Consultative Conference, and will focus on the field of translational medicine.